Q4収益の急上昇とEPSの欠損にもかかわらず、シュロダーズはIlumina所持率を32.5%増した. Schroders increased Illumina holdings by 32.5%, despite Q4 revenue surge and EPS miss.

Q4では,DFデント&CoとCalppersはイルミナで投資を削減し,シュロダー投資管理は32.5%増加し,48263株を購入した. In Q4, DF Dent & Co. and CalPERS reduced their stakes in Illumina, while Schroder Investment Management increased its holdings by 32.5%, buying 48,263 shares. 遺伝子分析会社イルミナは770.7%の収益の飛躍を報告したが,EPSの見積りは0.06ドルを逃した. Illumina, a genetic analysis company, reported a 720.7% revenue jump but missed EPS estimates by $0.06. 株価は1297億ドルで,コンセンサス価格目標は140.90ドルです. The stock has a market cap of $12.97 billion, with a consensus price target of $140.90.